Nachman Norwood & Parrott’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Nachman Norwood & Parrott’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$292K	Buy	+28	New	+$235K	0.03%	240

Other funds holding IRLA

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SUT

SC US (TTGP) Menlo Park, California $31.9B AUM 28.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Nachman Norwood & Parrott's IRLA Position: Q2 2021 in Review

Nachman Norwood & Parrott opened a new position in IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2021: 28 shares worth $292K. The stake represents 0.03% of the portfolio and ranks #240 among its holdings.

100 funds tracked by Wall St. Rank hold IRLA as of Q2 2021.

Nachman Norwood & Parrott held 28 shares of IRulya Therapeutics Inc. Common Stock worth $292K as of Q2 2021.
IRulya Therapeutics Inc. Common Stock was a new Nachman Norwood & Parrott position in Q2 2021.
IRulya Therapeutics Inc. Common Stock made up 0.03% of Nachman Norwood & Parrott's portfolio in Q2 2021, its #240 holding.
100 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2021.

Based on Nachman Norwood & Parrott's 13F filing for Q2 2021, filed 13 Aug 2021.